



## Correction to: Pigment Epithelium-Derived Factor Improves Paracellular Blood–Brain Barrier Integrity in the Normal and Ischemic Mouse Brain

Arina Riabinska<sup>1,3</sup> · Marietta Zille<sup>2,4</sup> · Menderes Yusuf Terzi<sup>1,5</sup> · Ryan Cordell<sup>1</sup> · Melina Nieminen-Kelhä<sup>1</sup> · Jan Klohs<sup>2,6,7</sup> · Ana Luisa Piña<sup>1</sup>

Published online: 18 May 2020  
© Springer Science+Business Media, LLC, part of Springer Nature 2020

### Correction to: Cellular and Molecular Neurobiology <https://doi.org/10.1007/s10571-019-00770-9>

The original version of the article unfortunately contained an error in the unit of the protein concentrations under ‘Stereotactic Intraparenchymal Injections’ subsection in ‘Methods’ section.

The unit should be ng/μl instead of ng/ml.  
Therefore, the sentence should read as follows:

For the claudin-5 expression study, solutions with the following protein concentrations were prepared: 40 ng/μl VEGF (group VEGF alone), 40 ng/μl VEGF and 40 ng/μl PEDF (group VEGF:PEDF 1:1), and 40 ng/μl VEGF and 80 ng/μl PEDF (group VEGF:PEDF 1:2).

---


The original article can be found online at <https://doi.org/10.1007/s10571-019-00770-9>.

---

✉ Ana Luisa Piña  
ana-luisa.pina@charite.de

- <sup>1</sup> Department of Neurosurgery, Experimental Neurosurgery/BCRT, Charite-Universitätsmedizin Berlin, Campus Mitte, Chariteplatz 1/Virchowweg 21, Aschheim-Zondek-Haus 03-003, 10117 Berlin, Germany
- <sup>2</sup> Department of Experimental Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany
- <sup>3</sup> Department of Internal Medicine, Medical Clinic I, University Hospital of Cologne, Cologne, Germany
- <sup>4</sup> Institute for Experimental and Clinical Pharmacology and Toxicology, University of Lübeck, Lübeck, Germany
- <sup>5</sup> Department of Medical Biology, Hatay Mustafa Kemal University, Antakya, Hatay, Turkey
- <sup>6</sup> Institute for Biomedical Engineering, ETH and University of Zurich, Zurich, Switzerland
- <sup>7</sup> Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland

Accordingly, the caption of Fig. 1 should be as follows:



**Fig. 1** The Co-injection of PEDF after VEGF-induced hyperpermeability reduces the paracellular blood–brain barrier disruption. **a** We wanted to confirm that VEGF induces hyperpermeability in the brain. Therefore, we administered intraparenchymal injection of 40 ng/μl VEGF or CSF to the brain. VEGF did not significantly induce the transcellular extravasation of Evans Blue (expressed as the fold change to CSF,  $n=3$ ). However, we recognize that the sample size was likely not large enough to show statistical significance. **b** Compared to VEGF alone (40 ng/μl), the coadministration of PEDF (40 ng/μl) did not change the Evans Blue extravasation ( $n=6$ ). **c**

Shown are representative pictures from the claudin-5 (Cln-5) stained brain samples in mice receiving an intraparenchymal injection of CSF, VEGF, or VEGF+PEDF. Scale bar = 100 μm. **d** The number of claudin-5-immunoreactive vessels significantly increased after the VEGF+PEDF (40 ng/μl VEGF and 40 ng/μl PEDF for VEGF:PEDF 1:1,  $n=11$ ; 40 ng/μl VEGF and 80 ng/μl PEDF for VEGF:PEDF 1:2,  $n=9$ ) compared to the 40 ng/μl VEGF-only treatment, indicating an improved paracellular BBB integrity. The data are represented as medians, except for the amount of claudin-5-immunoreactive vessels in VEGF+PEDF 1:2 that is presented as mean ± SD,  $*p < 0.05$

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.